stockrow
Friday 6 November 2026
Export TELO’s income statement to Excel — free account
Telomir Pharmaceuticals, Inc.
TELO Healthcare Biotechnology
- EPS
- −364.7%
- Free cash flow
- −45.3%
Quarter to June 2026, against a year earlier
0.73
0.05
−6.41%
Follow TELO
Alert me
Telomir Pharmaceuticals, Inc. (TELO) P/E ratio
Telomir Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XBIT XBiotech Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | n/m |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| CLNN Clene Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. | n/m |
| XLO Xilio Therapeutics, Inc. compare | n/m |
| SPRO Spero Therapeutics, Inc. compare | 7.4× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)